[Changes in ovarian function and ovarian reserve after combined treatment for differentiated thyroid cancer].
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
BACKGROUND: The paradigm of combined treatment for differentiated thyroid cancer has been in use since the mid-20th century. This approach involves thyroidectomy, followed by radioactive iodine therapy, and after patients may be prescribed suppressive therapy. Combined treatment improves outcomes, particularly in cases of high risk of recurrence. However, it can also lead to a range of secondary complications, including those affecting the reproductive system. AIM: Assessment and comparative analysis of ovarian function and ovarian reserve (OR) using anti-Müllerian hormone (AMH), follicle-stimulating hormone (FSH), luteinizing hormone (LH), prolactin (PRL), estradiol (E2) and estrone (E1) in the early follicular phase in women of reproductive age who received combined treatment for DTC, and in healthy women of the same age. MATERIALS AND METHODS: In a single-center, comparative cross-sectional study, clinical and morphological, anamnestic and laboratory parameters were analyzed in patients who underwent thyroidectomy and one course of radioiodine therapy for DTC, and in healthy women. RESULTS: The study enrolled 90 women aged 18 to 40 years: 67 women with DTC with a median age of 31 years [26; 36] who underwent combined treatment, and 30 healthy women with a median age of 30 years [28; 35]. The frequency of menstrual cycle disorders over the past year was 33% in women with DPT and 13% in healthy women.When comparing the results of hormonal examination, it was revealed that the levels of FSH, LH, PRL, E1 and E2 did not differ significantly between the groups. The level of AMH was the only parameter that significantly differed in patients with DTC receiving combined treatment and in healthy women - 2.49 ng/ml [1.1; 3.3] and 3.6 ng/ml [2.62; 4.18], respectively (P < 0.004). In 18 (27%) patients with DTC, the level of AMH was < 1.2 ng/ml, in the group of healthy women low level of AMH was found only in one case. Only patient's age at the time of RAIT and age at the time of examination on the background of thyroid stimulating hormone suppression were associated with diminished ovarian reserve, using the Juden index, the cut-off points of 31 years and 33 years were determined, respectively. CONCLUSION: The level of AMH in patients with DTC who undergo combined treatment is significantly lower compared to healthy women of the same age. Only patient's age at the time of RAIT and age at the time of examination on the background of thyroid stimulating hormone suppression were associated with diminished ovarian reserve.